FGF2 and AL amyloidosis: Formononetin has been found to suppress fibroblast growth factor 2 (FGF2)-induced STAT3 activation, successfully suppressing multiple myeloma, leukemia, lymphoma and solid tumors that display constitutive STAT3 activation [121].